Section 1 of 4Overview

Overview

An approved long-acting GnRH agonist depot used in the United States for palliative treatment of advanced prostate cancer.

Primary regulatory source

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.

Section 2 of 4Identity and mechanism

Identity and mechanism

Initial receptor stimulation is followed by pituitary GnRH-receptor desensitization and suppression of LH, FSH and gonadal sex hormones.

PubChem CID 25074470; C64H82N18O13; 1311.4 Da.

Section 3 of 4Regulatory label facts

Regulatory label facts

FDA (United States; Trelstar for advanced prostate cancer).

The dose below reproduces a regulator-approved label; it is not a treatment recommendation. Trelstar intramuscular depot: 3.75 mg every 4 weeks, 11.25 mg every 12 weeks, or 22.5 mg every 24 weeks.

Section 4 of 4Safety boundary

Safety boundary

Treatment can cause an initial tumor flare, hot flushes, metabolic and cardiovascular effects, QT prolongation and loss of bone density; the label requires clinical monitoring.

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.